+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Premature Ejaculation Treatment Market Research Report by Drug Type, Type, Dosage Form, Distribution Channel, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 5124366
  • Report
  • April 2022
  • Region: United States
  • 102 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022
The United States Premature Ejaculation Treatment Market size was estimated at USD 596.54 million in 2021, USD 686.95 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 11.55% to reach USD 1,149.96 million by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Premature Ejaculation Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Type, the market was studied across Dapoxetine, Phosphodiesterase Type 5 (PDE5) Inhibitors, Selective Serotonin Reuptake Inhibitors (SSRIs), Topical Anesthetics, and Zertane.
  • Based on Type, the market was studied across Oral Therapies and Topical Therapies. The Oral Therapies is further studied across Nonselective Serotonin Reuptake Inhibitor and Selective Serotonin Reuptake Inhibitor.
  • Based on Dosage Form, the market was studied across Pills and Spray.
  • Based on Distribution Channel, the market was studied across Hospitals, Online Pharmacies, and Retail Pharmacies.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Premature Ejaculation Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Premature Ejaculation Treatment Market, including Absorption Pharmaceuticals LLC, Akorn Pharmaceuticals, Allergan, Inc, Ampio Pharmaceuticals, Inc., Aytu BioScience, Bayer AG, Dong-A Pharmaceutical Co., Ltd, Eli Lilly and Company, Emcure Pharmaceuticals, Furiex Pharmaceuticals, Inc., Futura Medical PLC, GlaxoSmithKline plc, Hetero Healthcare Ltd, Innovus Pharmaceuticals, Janssen Pharmaceutica N. V, lpha Digital Health Pvt. Ltd, Menarini Group, NeuroHealing Pharmaceuticals, NeuroHealing Pharmaceuticals Inc., Pfizer Inc, Plethora Solutions Holdings Plc, Regent Pacific Group Limited, Veru Inc., WHOLESOME MEDTECH PRIVATE LIMITED, and zr pharma& GmbH.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Premature Ejaculation Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Premature Ejaculation Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Premature Ejaculation Treatment Market?
4. What is the competitive strategic window for opportunities in the United States Premature Ejaculation Treatment Market?
5. What are the technology trends and regulatory frameworks in the United States Premature Ejaculation Treatment Market?
6. What is the market share of the leading vendors in the United States Premature Ejaculation Treatment Market?
7. What modes and strategic moves are considered suitable for entering the United States Premature Ejaculation Treatment Market?
Frequently Asked Questions about the U.S. Premature Ejaculation Treatment Market

What is the estimated value of the U.S. Premature Ejaculation Treatment Market?

The U.S. Premature Ejaculation Treatment Market was estimated to be valued at $596.5 Million in 2021.

What is the growth rate of the U.S. Premature Ejaculation Treatment Market?

The growth rate of the U.S. Premature Ejaculation Treatment Market is 11.5%, with an estimated value of $1150.0 Million by 2027.

What is the forecasted size of the U.S. Premature Ejaculation Treatment Market?

The U.S. Premature Ejaculation Treatment Market is estimated to be worth $1150.0 Million by 2027.

Who are the key companies in the U.S. Premature Ejaculation Treatment Market?

Key companies in the U.S. Premature Ejaculation Treatment Market include Absorption Pharmaceuticals LLC, Akorn Pharmaceuticals, Allergan, Inc, Ampio Pharmaceuticals, Inc., Aytu BioScience, Bayer AG, Dong, A Pharmaceutical Co., Ltd and Emcure Pharmaceuticals.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Premature Ejaculation Treatment Market, by Drug Type
6.1. Introduction
6.2. Dapoxetine
6.3. Phosphodiesterase Type 5 (PDE5) Inhibitors
6.4. Selective Serotonin Reuptake Inhibitors (SSRIs)
6.5. Topical Anesthetics
6.6. Zertane
7. Premature Ejaculation Treatment Market, by Type
7.1. Introduction
7.2. Oral Therapies
7.2.1. Nonselective Serotonin Reuptake Inhibitor
7.2.2. Selective Serotonin Reuptake Inhibitor
7.3. Topical Therapies
8. Premature Ejaculation Treatment Market, by Dosage Form
8.1. Introduction
8.2. Pills
8.3. Spray
9. Premature Ejaculation Treatment Market, by Distribution Channel
9.1. Introduction
9.2. Hospitals
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. California Premature Ejaculation Treatment Market11. Florida Premature Ejaculation Treatment Market12. Illinois Premature Ejaculation Treatment Market13. New York Premature Ejaculation Treatment Market14. Ohio Premature Ejaculation Treatment Market15. Pennsylvania Premature Ejaculation Treatment Market16. Texas Premature Ejaculation Treatment Market
17. Competitive Landscape
17.1. FPNV Positioning Matrix
17.1.1. Quadrants
17.1.2. Business Strategy
17.1.3. Product Satisfaction
17.2. Market Ranking Analysis
17.3. Market Share Analysis, By Key Player
17.4. Competitive Scenario
17.4.1. Merger & Acquisition
17.4.2. Agreement, Collaboration, & Partnership
17.4.3. New Product Launch & Enhancement
17.4.4. Investment & Funding
17.4.5. Award, Recognition, & Expansion
18. Company Usability Profiles
18.1. Absorption Pharmaceuticals LLC
18.2. Akorn Pharmaceuticals
18.3. Allergan, Inc
18.4. Ampio Pharmaceuticals, Inc.
18.5. Aytu BioScience
18.6. Bayer AG
18.7. Dong-A Pharmaceutical Co., Ltd
18.8. Eli Lilly and Company
18.9. Emcure Pharmaceuticals
18.10. Furiex Pharmaceuticals, Inc.
18.11. Futura Medical PLC
18.12. GlaxoSmithKline plc
18.13. Hetero Healthcare Ltd
18.14. Innovus Pharmaceuticals
18.15. Janssen Pharmaceutica N. V
18.16. lpha Digital Health Pvt. Ltd
18.17. Menarini Group
18.18. NeuroHealing Pharmaceuticals
18.19. NeuroHealing Pharmaceuticals Inc.
18.20. Pfizer Inc
18.21. Plethora Solutions Holdings Plc
18.22. Regent Pacific Group Limited
18.23. Veru Inc.
18.24. WHOLESOME MEDTECH PRIVATE LIMITED
18.25. zr pharma& GmbH
19. Appendix
19.1. Discussion Guide
19.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET: DYNAMICS
FIGURE 2. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DRUG TYPE, 2021 VS 2027 (%)
FIGURE 3. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DRUG TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DRUG TYPE, 2027
FIGURE 5. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DAPOXETINE, 2019-2027 (USD MILLION)
FIGURE 6. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DAPOXETINE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 7. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS, 2019-2027 (USD MILLION)
FIGURE 8. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 9. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS), 2019-2027 (USD MILLION)
FIGURE 10. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS), BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 11. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL ANESTHETICS, 2019-2027 (USD MILLION)
FIGURE 12. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL ANESTHETICS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 13. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ZERTANE, 2019-2027 (USD MILLION)
FIGURE 14. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ZERTANE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 15. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 16. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TYPE, 2027
FIGURE 18. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ORAL THERAPIES, 2019-2027 (USD MILLION)
FIGURE 19. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ORAL THERAPIES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 20. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NONSELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2019-2027 (USD MILLION)
FIGURE 21. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NONSELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 22. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2019-2027 (USD MILLION)
FIGURE 23. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 24. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL THERAPIES, 2019-2027 (USD MILLION)
FIGURE 25. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL THERAPIES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 26. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2021 VS 2027 (%)
FIGURE 27. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2021 VS 2027 (USD MILLION)
FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2027
FIGURE 29. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PILLS, 2019-2027 (USD MILLION)
FIGURE 30. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PILLS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 31. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SPRAY, 2019-2027 (USD MILLION)
FIGURE 32. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SPRAY, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 33. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 34. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD MILLION)
FIGURE 35. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2027
FIGURE 36. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOSPITALS, 2019-2027 (USD MILLION)
FIGURE 37. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOSPITALS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 38. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2019-2027 (USD MILLION)
FIGURE 39. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 40. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2019-2027 (USD MILLION)
FIGURE 41. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 42. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET: FPNV POSITIONING MATRIX
FIGURE 43. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 44. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES PREMATURE EJACULATION TREATMENT MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 4. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DAPOXETINE, BY STATE, 2019-2027 (USD MILLION)
TABLE 5. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS), BY STATE, 2019-2027 (USD MILLION)
TABLE 7. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL ANESTHETICS, BY STATE, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ZERTANE, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 10. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ORAL THERAPIES, BY STATE, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NONSELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY STATE, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL THERAPIES, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2019-2027 (USD MILLION)
TABLE 15. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PILLS, BY STATE, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SPRAY, BY STATE, 2019-2027 (USD MILLION)
TABLE 17. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 18. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOSPITALS, BY STATE, 2019-2027 (USD MILLION)
TABLE 19. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY STATE, 2019-2027 (USD MILLION)
TABLE 20. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2019-2027 (USD MILLION)
TABLE 21. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET: SCORES
TABLE 22. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET: BUSINESS STRATEGY
TABLE 23. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET: PRODUCT SATISFACTION
TABLE 24. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET: RANKING
TABLE 25. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 26. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET: MERGER & ACQUISITION
TABLE 27. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 28. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 29. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET: INVESTMENT & FUNDING
TABLE 30. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 31. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET: LICENSE & PRICING

Companies Mentioned

  • Absorption Pharmaceuticals LLC
  • Akorn Pharmaceuticals
  • Allergan, Inc
  • Ampio Pharmaceuticals, Inc.
  • Aytu BioScience
  • Bayer AG
  • Dong-A Pharmaceutical Co., Ltd
  • Eli Lilly and Company
  • Emcure Pharmaceuticals
  • Furiex Pharmaceuticals, Inc.
  • Futura Medical PLC
  • GlaxoSmithKline plc
  • Hetero Healthcare Ltd
  • Innovus Pharmaceuticals
  • Janssen Pharmaceutica N. V
  • lpha Digital Health Pvt. Ltd
  • Menarini Group
  • NeuroHealing Pharmaceuticals
  • NeuroHealing Pharmaceuticals Inc.
  • Pfizer Inc
  • Plethora Solutions Holdings Plc
  • Regent Pacific Group Limited
  • Veru Inc.
  • WHOLESOME MEDTECH PRIVATE LIMITED
  • zr pharma& GmbH

Methodology

Loading
LOADING...